Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Press Releases 2008

SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness
[ December 11, 2008 ]
“SCYNEXIS believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases,” said SCYNEXIS President & CEO Yves Ribeill. “We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness.”

More

Positive Results for Improved Treatment Against Sleeping Sickness
[ New Orleans, USA; Paris, France; Geneva, Switzerland - December 9, 2008]
Pivotal Phase III clinical trial results conclusively show that Nifurtimox-Eflornithine Combination Therapy (NECT) is well tolerated and effective against the advanced stage of T. b. gambiense sleeping sickness, a fatal disease that threatens 60 million people in sub-Saharan Africa. [Français] [Español]

More

Coarsucam™ (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO Prequalification
- Significant Step towards Expanded Global Access to Malaria Treatment -
[ Paris, France, and Geneva, Switzerland - October 16, 2008]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the approval, by the World Health Organization (WHO) Prequalification of Medicines Program, of Coarsucam™ / Artesunate Amodiaquine Winthrop® (“ASAQ”), the first fixed-dose combination of the two antimalarial compounds, artesunate (AS) and amodiaquine (AQ). [Français]

More

Indian Scientists Catalyse Efforts in Research and Development for New Treatments for Neglected Diseases
[ New Dehli - October 13, 2008]
More than 100 scientists and researchers convene in New Delhi to discuss the present and future role of India in research and development (R&D), access, and capacity strengthening to develop and deliver new treatments needed by neglected patients. [Hindi]

More

Chagas Disease Partnership Will Deliver Safe, Easy-to-Use Treatment for Children
[ Geneva; Switzerland and Recife, Brasil -  July 21st, 2008]
An agreement between Drugs for Neglected Diseases initiative (DNDi) and the Pharmaceutical Laboratory of Pernambuco (Lafepe) will deliver the first pediatric formulation of benznidazole, the most widely used drug for the treatment of Chagas disease, at cost and for worldwide distribution. [Español] [Português]

More

Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed-dose combination “ASAQ” at equally low prices
[ Paris, France, and Geneva, Switzerland - July 21st, 2008]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price levels of Artemisinin-based Combination Therapies (ACT). [Français]

More

DNDi calls on G8 leaders to increase their commitment to neglected tropical diseases
[ Geneva - June 30, 2008 ]
Immediately following the Drugs for Neglected Diseases initiative (DNDi) Stakeholders’ Meeting on June 26, 2008, and in advance of the upcoming 2008 G8 Summit in Japan, DNDi released a statement endorsed by World Health Organization (WHO) urging the G8 governments to support both control programs and research & development (R&D) initiatives for neglected tropical diseases.

More

DNDi Partners With Pharma, Biotech, Academia, Public Health Institutes & NGOs to Deliver Lifesaving Drugs
[ New York - June 23, 2008 ]
More Than 150 Scientists and Researchers from Around the World Convene in New York to Mobilize R&D Resources for Neglected Diseases. [Français]

More

Hope for Treating the Most Infectious and Neglected Diseases
[ Paris, Geneva - June 11, 2008 ]
Today, the Paris-based Institut de Recherche pour le Développement (IRD) and DNDi announced the implementation of scientific cooperation projects for developing treatments against visceral leishmaniasis, Chagas disease, and sleeping sickness. [Français]

More

The University of North Carolina and DNDi Agree to Synergize Novel R&D Efforts to Develop Drugs for the Most Neglected
[ Chapel Hill, USA; Geneva, Switzerland - June 4, 2008 ]
International fight against neglected tropical diseases strengthened by collaboration between two leading public-private partnerships to further development of safe and affordable drugs to fight diseases in the least developed countries.

More

DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected
[ Siena, Italy; Geneva, Switzerland - May 8, 2008 ]
The University of Siena today awarded the Drugs for Neglected Diseases initiative (DNDi) with a Goodwin Award for its innovative needs-driven approach in making 2 new antimalarials available as public goods, and in engaging public and private partners worldwide, especially in neglected disease-endemic countries, to ensure that the best science is made available for those neglected patients.

More

A Worldwide Public Partnership Makes Available a New, Once-a-Day Fixed-Dose Combination against Malaria
[ Rio de Janeiro - April 17, 2008 ]
An innovative partnership between the Brazilian public pharmaceutical company, Farmanguinhos/Fiocruz, and the non-profit drug development organization, Drugs for Neglected Diseases initiative (DNDi), announced today that ASMQ, the new fixed-dose combination of artesunate (AS) and mefloquine (MQ), is now registered and available in Brazil.  [Português] [Español] [Français] [Italiano]

More

Spanish government commits EUR 5 million to DNDi’s research for new medicines for neglected diseases
[ Madrid and Geneva - March 6, 2008 ]
Spain’s Agencia Española de Cooperación Internacional (AECI) today granted EUR 5.0 million to the Drugs for Neglected Diseases initiative (DNDi) for essential research and development (R&D) of drugs for neglected diseases such as human African trypanosomiasis, leishmaniasis, Chagas disease, and malaria. [Español] [PDF]

More

GlaxoSmithKline, Drugs for Neglected Diseases Initiative to Collaborate on Research Projects to Meet Public Health Needs in the Developing World
[ Tres Cantos, Spain; Geneva, Switzerland - March 6, 2008 ]
GlaxoSmithKline (GSK) and the not-for-profit organization, Drugs for Neglected Diseases initiative (DNDi), today announced a collaborative research effort targeting neglected tropical diseases which disproportionately affect the developing world. [Español] [PDF]

More

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License